Several studies have found that anti-TIGIT therapy alone achieved good efficacy in a few tumor models [7, 10] Pre-clinical and clinical trials have also found that anti-TIGIT therapy combined with anti-PD1 may obtain a certain curative effect, but that anti-TIGIT alone did not show statistically significant anti-tumor effects [12, 13]. The gene discussed is TIGIT; the disease is neoplasm.